Loading…
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2024
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2024 | $0M | $-16M | $-16M | $-7M | -623.1% | - | 77.6% |
| 2023 | $0M | $-9M | $-9M | $-6M | -132.7% | - | 13.6% |
| 2022 | $0M | $-8M | $-8M | $-6M | -59.2% | - | 71.2% |
| 2021 | $0M | $-5M | $-5M | $-4M | -17.0% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 4.60 | 8.04 | 9.33 | 16.01 |
| Research And Development | 3.56 | 6.48 | 7.70 | 12.95 |
| Selling General And Administration | 1.04 | 1.56 | 1.63 | 3.06 |
| Total Expenses | 4.60 | 8.04 | 9.33 | 16.01 |
| Operating Income | -4.60 | -8.04 | -9.33 | -16.01 |
| Total Operating Income As Reported | -4.60 | -8.04 | -9.33 | -16.01 |
| EBITDA | -4.59 | -8.04 | -9.32 | -16.01 |
| Normalized EBITDA | -4.59 | -8.04 | -9.32 | -16.01 |
| EBIT | -4.60 | -8.04 | -9.33 | -16.01 |
| Interest Income | 0.03 | 0.22 | 0.44 | 0.22 |
| Net Interest Income | 0.03 | 0.22 | 0.44 | 0.22 |
| Interest Income Non Operating | 0.03 | 0.22 | 0.44 | 0.22 |
| Net Non Operating Interest Income Expense | 0.03 | 0.22 | 0.44 | 0.22 |
| Pretax Income | -4.57 | -7.83 | -8.89 | -15.79 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | -4.57 | -7.83 | -8.89 | -15.79 |
| Net Income From Continuing And Discontinued Operation | -4.57 | -7.83 | -8.89 | -15.79 |
| Net Income From Continuing Operation Net Minority Interest | -4.57 | -7.83 | -8.89 | -15.79 |
| Net Income | -4.57 | -7.83 | -8.89 | -15.79 |
| Net Income Common Stockholders | -4.57 | -7.83 | -8.89 | -15.79 |
| Net Income Including Noncontrolling Interests | -4.57 | -7.83 | -8.89 | -15.79 |
| Normalized Income | -4.57 | -7.83 | -8.89 | -15.79 |
| Diluted NI Availto Com Stockholders | -4.57 | -7.83 | -8.89 | -15.79 |
| Basic Average Shares | 12.94 | 12.91 | 12.85 | 13.01 |
| Diluted Average Shares | 12.94 | 12.91 | 12.85 | 13.01 |
| Reconciled Depreciation | 0 | 0 | 0 | 0 |
| General And Administrative Expense | 1.04 | 1.56 | 1.63 | 3.06 |
| Other Gand A | 1.04 | 1.56 | 1.63 | 3.06 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Greenwich LifeSciences, Inc.this co. | GLSI | $347M | -21.99 | 136.99 | -623.1% | - |
| Puma Biotechnology, Inc. | PBYI | $357M | 11.47 | 2.74 | 23.9% | 6.67 |
| REGENXBIO Inc. | RGNX | $356M | -1.83 | 3.46 | -188.7% | -2.96 |
| Atea Pharmaceuticals, Inc. | AVIR | $354M | -2.23 | 1.28 | -57.5% | -1.43 |
| Larimar Therapeutics, Inc. | LRMR |
| $342M |
| - |
| 4.38 |
| -212.2% |
| - |
| Enanta Pharmaceuticals, Inc. | ENTA | $341M | -4.17 | 5.27 | -126.5% | -5.14 |
| Verastem, Inc. | VSTM | $339M | -1.62 | 5.93 | -366.2% | -1.07 |
| Simulations Plus, Inc. | SLP | $336M | -5.20 | 2.70 | -51.9% | 20.82 |
| 908 Devices Inc. | MASS | $334M | 17.11 | 2.32 | 13.6% | -12.61 |
| Peer Median | - | -1.83 | 3.10 | -92.0% | -1.43 | |